COmparison of Bleeding Risk between Rivaroxaban and Apixaban for the treatment of acute venous thromboembolism

The primary outcome is the rate of adjudicated clinically relevant bleeding (CRB) events defined as the composite of major bleeding (MB) events and/or clinically relevant non-major bleeding events (CRNMB).